2012-01-25
Continued high growth driven by ProbiMage and ProbiFrisk
Preliminary Annual Report 2011
Probi signs co-development agreement
2011-11-03
Probi signs co-development agreement with leading global food company
Probi has entered into a co-development agreement with a leading global food company focusing on joint clinical development of Probi’s immune health platform ProbiDefendumTM. The objective of the collaboration is to further strengthen the clinical platform of ProbiDefendumTM in preparation of the application for a health claim within the EU that Probi intends to make. A jointly conducted clinical trial on common colds and immune response will commence in Europe in Q1 2012. Probi’s partner has been granted an exclusive global option to negotiate commercial agreements where Probi currently has no commercial products based on the immune health platform.
Interim Report January – September 2011
2011-10-19
Continued high growth and US breakthrough for dietary supplements
Breakthrough for Probi in the U.S.
2011-08-25
Breakthrough for Probi in U.S. mass retail and mass drug VMS market
Probi has signed one of its most signficant dietary supplement agreements to date with Pharmavite, a leader in the US vitamin, minerals and supplement market (VMS). Pharmavite will launch Probi’s gut health capsules containing Lp299v™ at the beginning of 2012 under the Nature Made® brand – the leading U.S brand in VMS. The agreement is expected to generate between 5 and 10 MSEK in net revenue for Probi in 2012.
Probi repurchases treasury shares
2011-08-15
The Board of Directos of Probi AB has resolved to utilise the authorisation granted by the Annual General Meeting of Shareholders to repurchase shares in the company.
Probi has commenced the repurchase of treasury shares
2011-03-07
Probi has commenced the repurchase of treasury shares
The Board of Directos of Probi AB has resolved to utilise the authorisation granted by the Annual General Meeting of Shareholders to repurchase shares in the company.
Probi signs distribution agreement in Israel for dietary supplements
2011-02-03
Probi signs distribution agreement with Ta`am Teva Altman in Israel regarding Lp299v™ dietary supplements
Probi has signed an agreement giving Ta`am Teva Altman rights to launch Probi’s dietary supplement for gut health based on Lp299v™ in Israel. The launch is planned to take place in the second quarter of 2011.
Preliminary Annual Report 2010
2011-01-26
Probi’s best year yet, with an turnover increase of 23 percent and an EBIT increase of 31 percent
